SUMMARY Perhexiline maleate is an antianginal agent which depends on hepatic oxidation for its elimination. Its use may be complicated by the development of peripheral neuropathy and liver damage. The majority of patients with perhexiline neuropathy have an impaired ability to effect metabolic drug oxidation which is genetically determined. Information has not been available on drug oxidation capacity in patients with perhexiline liver injury. Drug oxidation was measured using an oxidation phenotyping procedure in four patients with perhexiline liver injury and in 70 patients with chronic liver disease serving as a control group. All four patients with perhexiline liver damage showed a substantial metabolic defect; three of the four patients (75%) showed a genetically determined impairment of oxidation capacity. The incidence of severely impaired oxidation capacity in the perhexiline group was significantly greater than in the patients with chronic liver disease (6/70; 8.6%) and in the healthy population (9%) (F=0.0048). A clear association exists between perhexiline liver injury and diminished drug metabolic activity, suggesting that the propensity to develop perhexiline liver injury is, at least in part, genetically determined. 
Perhexiline maleate (Pexid) has been used for the treatment of angina pectoris since 1974. Althou h clinical trials have shown its undoubted efficacy, 3 its use is associated with serious side effects such as weight loss,4 5 hypoglycaemia,6 proximal myopath ,7 peripheral neuropathy8 9 and hepatic damage. -12 The neuropathy and the hepatic damage may not reverse when the drug is withdrawn and deaths have been recorded. [11] [12] [13] [14] [15] [16] [17] [18] Severe adverse reactions follow the use of perhexiline in only a percentage of patients and are perhaps associated with impaired metabolism of the drug. Perhexiline is a lipophilic drug and its elimination depends on hepatic oxidation to the more polar monohydroxylated and dihydroxylated metabolites.19 Several oxidising ability cannot be measured using perhexiline but is readily determined using debrisoquine. 21 22 It has been shown recently that the majority of patients who develop perhexiline neuropathy show impaired drug oxidising ability suggesting that the susceptibility to perhexiline neuropathy is largely genetically determined. 23 No study of a similar nature has been undertaken in patients with perhexiline related liver injury.
This paper reports the results of oxidation phenotyping in four patients with perhexiline liver injury. Liver damage itself may be associated with impaired oxidation capacity24 thus 70 patients with chronic liver disease were studied as a control group. Patients with alcohol related liver injury were excluded from the control group because an individual's susceptibility to develop alcohol related liver injury is probably at least in part genetically determined. Although ethanol is metabolised mainly by the alcohol dehydrogenase pathway there capacity might predispose to alcohol related liver injury.
Case histories TB, a man aged 54 years, was admitted in March 1980 with a six week history of episodes of giddiness and loss of consciousness. He had recently lost weight. His angina had been treated since early 1977 with perhexiline, 300 mg daily. He had never abused alcohol and his weekly intake averaged less than 20 g. He had taken anticoagulants for several years.
On examination there were signs of mitral stenosis and incompetence, of an old left hemiplegia, and of a sensory peripheral neuropathy. The liver was enlarged 5 cm below the right costal margin.
Investigations on admission showed: serum bilirubin 17,umol/l; 1 mg/100 ml (reference range 5-17 ,umol/l; 0-3-1 mg/100 ml), serum aspartate transaminase (AST) 127 U/l (5-40), serum alkaline phosphatase (ALP) 196 U/l; 28 KAu/100 ml (30-110 U/l; 3-13 KAu/100 ml), plasma albumin 31 g/l; 3 1 g/100 ml (35-50 g/l; 3 5-5 0 g/100 ml), prothrombin time (PT) (off warfarin), 15s (control 13s), serum HBsAg, smooth muscle (SMA), mitochondrial (AMA) and nuclear (ANF) antibodies negative, serum creatinine 107 /mol/l; 1-3 mg/100 ml (60-120
,umol/l; 0-7-1-4 mg/100 ml On examination her liver was enlarged 7 cm below the right costal margin and the spleen tip could be felt.
Investigations on admission showed: bilirubin 17 ,umol/l (1 mg/100 ml), AST 490 U/l, ALP 112 U/l (16 KAu/100 ml), albumin 36 g/l (3.6 g/100 ml), PT 17s, HBsAg, SMA, AMA, ANF negative, creatinine 72 ,mol/l (0.8 mg/100 ml). Liver biopsy showed a micronodular cirrhosis with necrosis, inflammation and numerous Mallory bodies (Fig. 1) .
Perhexiline was withdrawn; six months later the patient was clinically improved, the liver function tests showed only minimal abnormalities but the hepatosplenomegaly was unchanged.
AG, a woman aged 69 years, was admitted in January 1982 with a three month history of anorexia, weight loss and abdominal distension. Her angina had been treated for three years with perhexiline, 300 mg daily. She had never abused alcohol and drank minimal quantities at Christmas time only.
On examination she was mildly jaundiced and the liver was enlarged 10 cm below the right costal margin. There was moderate ascites and a mild sensory peripheral neuropathy.
Investigations on admission showed: bilirubin 21
,umol/l (1.2 mg/100 ml), AST 213 U/l, ALP 256 U/l (36 KAu/100 ml), albumin 29 g/l (2.9 g/100 ml), PT 19s, HBsAg, SMA, AMA, ANF negative, creatinine 64 umol/l (0.7 mg/100 ml). Liver biopsy showed a micronodular cirrhosis with massive accumulation of Mallory bodies and associated neutrophils, but only very mild fatty change (Fig. 2) . Perhexiline was withdrawn but the patient developed increasing hepatocellular failure and died one month after admission.
Methods

PATIENTS
The study group comprised the four patients with perhexiline liver damage. The control group comprised 70 inpatients/outpatients with biopsy proven chronic liver disease. Patients were excluded from the control group if they had alcohol related All patients were phenotyped for oxidation status using debrisoquine. After an overnight fast a single 10 mg oral dose of debrisoquine (Declinax 10, Roche) was taken. The urine passed in the subsequent eight hours was collected in bulk, the volume measured and a 20 ml sample stored at -20°C until analysis. Each sample was analysed for its content of parent drug and its major metabolite, 4-hydroxydebrisoquine using electron capture gas chromatography. For each patient a metabolic ratio was calculated which defined that individual's ability to metabolise the drug: Debrisoquine metabolic ratio % excreted as unchanged debrisoquine % excreted as 4-hydroxy-debrisoquine in the 0-8 hour urine.
Values In all subjects studied routine biochemical tests and oxidation phenotyping were performed in the same 24 hour period.
Correlations between variables were performed by linear least squares regression analysis.
Results
The perhexiline study group comprised three women and one man, mean age 62 years. One female patient smoked, none abused alcohol and most took other medication. The length of treatment and the total dose of perhexiline consumed, the clinical and histological features of toxicity and outcome after drug withdrawal varied (Table 1) . In three patients (TB, DW, and SP) debrisoquine phenotyping was undertaken at least eight weeks after perhexiline was withdrawn at which time liver function was improving. In the remaining patient (AG) phenotyping was undertaken one week after drug withdrawal when liver function was deteriorating. All four patients showed metabolic ratios >1; three patients (75%) were phenotypically PM with ratios >12-6 ( Table 2) .
The control group comprised 54 women and 16 men (3F: 1M), mean age 49-6 years. Their liver disease varied in aetiology and severity. Thirteen patients had cryptogenic cirrhosis, 27 primary biliary cirrhosis, 24 chronic active hepatitis and six miscellaneous liver diseases; none was severely decompensated. Very few patients smoked and none abused alcohol ( Table 3 ). The majority took prescribed medication including prednisolone (17 patients) and d-penicillamine (10 patients). The metabolic ratios in the control group ranged from 0-1 to 45.1 with a median value of 1*2. Thirty two patients (45.7%) had a ratio of <1, while six (8.6%) had ratios >12-6. The remaining 32 patients (45.7%) showed intermediate values (Table 3) .
The proportion of patients in the study group with high metabolic ratios (3/4) was significantly greater than in the control group (6/70) (Fischer's exact probability F=0*0048). Urinary recoveries of debrisoquine and its metabolite were comparable in the perhexiline study group and in controls.
In the control group no correlation existed between the metabolic ratio and the age or sex of the patient or with any particular pattern of cigarette or drug ingestion. Equally no significant relationship existed between the metabolic ratio and values for serum bilirubin (r=-0.014; p>0.1), serum AST (r=-0.014; p>0.1), serum ALP (r=-0-086; p>0.1),.plasma albumin (r=-0-206; 0O1>p>0 05) or PT (r=0-222; 0.1>p>0.05).
Discussion
Although a dose dependent increase in trans- Bilirubin: ,umol/l x 0-585 = mg/100 ml. ALP: U/i x 0-141 = KAu/100 ml. Albumin: g/l x 0.1 = g/100 ml.
Creatinine: Amol/l x 0.0113 = mg/100 ml. undertaken. In the series reported to date 18
The incidence of liver injury during prolonged patients have shown non-specific hepatitis with or treatment with perhexiline is unknown. Following without fatty infiltration, 11 27 33-5 two a 600 mg of perhexiline daily for several months, granulomatous hepatitis,35 36 --9  57  --8  28  --18  49  --18  30  --8  28  --16  14  --18  69  --6  32  9  35  --9  30  --18  28  --86  163   232  82  146  90  82  112  411  131  232  63  72  820   39  47  36  41  47  31   40   46  38  46  44  39   12  13  16  16  13  18  13  13  13  13  13  12   63  110  75  71  110  73  99  93  66  95  79 The liver damage in the present four patients almost certainly resulted from perhexiline. None of the patients consumed excessive quantities of alcohol nor took other, potentially hepatotoxic drugs. Other manifestations of perhexiline toxicity were present; two patients showed disturbed balance (TB, DW), three showed significant weight loss (TB, DW, AG), three had peripheral neuropathy (TB, DW, AG) and one a proximal myopathy (DW). The liver lesions were similar to those already described following perhexiline and no other cause for the liver disease was found. Withdrawal of the drug resulted in a prompt improvement in the clinical condition and some biochemical tests in two patients; the remaining two patients deteriorated despite drug withdrawal, a course already well recognised after perhexiline liver injury.' 2 13 15 17 18 30 Severe hepatotoxicity only occurs in a percentage of perhexiline treated patients. In the present study all four patients with perhexiline liver injury showed diminished drug elimination ability as measured by debrisoquine hydroxylation. In three of the four patients the metabolic ratio exceeded 12-6 indicating the PM phenotype. In the control group of 70 patients with chronic liver disease the proportion of patients with the PM phenotype was similar to that in the healthy population22 and there was no correlation between oxidation capacity and standard liver function tests. Thus the impairment of drug oxidation ability in the perhexiline damaged patients can not be explained simply on the basis of impaired hepatocellular function.
A clear association therefore exists between perhexiline liver injury and diminished drug oxidation capacity. As a result of impaired drug oxidation, Perhexiline would be expected to accumulate' and this might explain the toxic sequelae. The actual mechanism of the toxic reaction is unknown, but drug induced disturbances of phospholipid metabolism have been implicated. 12 One of the four patients studied had a metabolic ratio of 2-6 which indicates a substantial metabolic impairment, but not the PM phenotype. Thus although drug oxidation status may be a major determinant of both therapeutic and toxic drug responses, other factors must also be important; HLA. B8 might be one such factor. 42 Perhexiline 
